Skip to main content

Table 3 C-statistic (with 95% confidence interval) for the association of recurrence-free survival (in days) using a Cox regression model controlling for patient age, race, and hormone receptor status

From: Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer

 

C-statistic

Most enhancing tumor volume METV (automated)

Functional tumor volume FTV (semi-manual) [8]

Pre-treatment baseline

0.69 [0.58; 0.80]

0.67 [0.55;0.79]

Early treatment

0.72 [0.60; 0.84]

0.70 [0.58; 0.82]

Delta (early treatment-baseline)

0.62 [0.50; 0.75]

0.64 [0.50; 0.78]